Assistant Professor of Medicine, Massachusetts General Hospital
Oncology
Dr. Marc D. Michaelson, MD
|
|
Give Review
Marc D. Michaelson works in the field of Oncology. He graduated from Albert Einstein College of Medicine of Yeshiva University. He received 1 awards: "Regional Top Doctor". Dr. Marc D. Michaelson is a published doctor and has 26 publications published. The lastest was: 'Three Synchronous Atypical Metastases of Clear Cell Renal Carcinoma to the Maxillary Gingiva, Scalp and the Distal Phalanx of the Fifth Digit: A Case Report.' Marc Michaelson accepts Medicare payments and is registered with Medicare.gov.
Publications
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
- Sunitinib-associated hypertension and Neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
- Kidney Cancer, version 3.2015.
- Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostat...
- Axitinib versus sorafenib in advanced renal cell carcinoma: subAnalyses by prior therapy from a randomised phase III trial.
- Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
- Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer.
- Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
- Kidney Cancer, version 2.2014.
- Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer.
- Medical Oncology Consultation and Minimization of Overtreatment in Men With Low-Risk Prostate Cancer.
- Prognostic significance of indeterminate Lung nodules in renal cell carcinoma.
- Models of Care and NCCN Guideline Adherence in Very-Low-Risk Prostate Cancer.
- Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carc...
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival Analysis and updated results from a randomised phase 3 trial.
- A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases.
- Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
- Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitin...
- Multidisciplinary Care and Pursuit of Active Surveillance in Low-Risk Prostate Cancer.
- Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targete...
- Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
- Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate Cancer.
- Combination of targeted agents in metastatic renal cell carcinoma: A path forward or a dead-end street?
- Three Synchronous Atypical Metastases of Clear Cell Renal Carcinoma to the Maxillary Gingiva, Scalp and the Distal Phalanx of the Fifth Digit: A Case Report.
Schools
Albert Einstein College of Medicine of Yeshiva University
Brigham and Women39s Hospital
Dana Farber Cancer Institute
Massachusetts General Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Brigham and Women's Hospital -
Albert Einstein College of Medicine of Yeshiva University
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1275523490 | |
| NPPES Provider LastName | MICHAELSON | |
| NPPES Provider FirstName | MARC | |
| NPPES Provider ZIPCode | 021142621 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 182.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1275523490 |
| Last Name Of The Provider | MICHAELSON |
| First Name Of The Provider | MARC |
| View All |
Similar Doctors
|
|
Dr. Ronald W. Takvorian, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew J. Yee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lecia V. Sequist, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Alison M. Schram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John K. Erban III, MD
This Doctor is OpenDoctor Recommended.
|